Cash, cash equivalents and marketable securities as of March 31, 2025 totaled $43.0 million.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Ovid Therapeutics Advances Pipeline Amid Financial Progress
- Ovid Therapeutics price target lowered to $4 from $5 at BTIG
- Ovid Therapeutics: Strategic Pipeline Reprioritization and Promising KCC2 Portfolio Drive Buy Rating
- Ovid Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
- Applied Therapeutics appoints Baumgartner as Chief Regulatory Officer